ADIAL PHARMACEUTICALS, INC. (ADIL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-09

Key Insights

Adial Pharmaceuticals granted restricted stock awards to its named executive officers, including the CEO, CFO, and COO, as part of their compensation arrangements.
The restricted stock awards vest in full on the earlier of one year from the grant date or upon a change of control event, aligning the executives' interests with shareholders.
The company also granted restricted stock awards and stock options to its board of directors as compensation for their service, further strengthening the alignment between management, the board, and shareholders.

Want the newest filings?

This analysis covers the filing from 2026-04-09. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-06

Adial Pharmaceuticals reported its financial results for the fiscal year ended December 31, 2025, providing investors with an update on the company's performance.
The press release attached to the 8-K filing contains the financial information, which investors can review to assess the company's financial health and growth trajectory.
As an emerging growth company, Adial Pharmaceuticals may have opted to use the extended transition period for complying with new or revised financial accounting standards, which could impact the comparability of its financial statements.

Other reports for ADIAL PHARMACEUTICALS, INC.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.